These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 30940536

  • 1. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.
    Laprairie RB, Bagher AM, Rourke JL, Zrein A, Cairns EA, Kelly MEM, Sinal CJ, Kulkarni PM, Thakur GA, Denovan-Wright EM.
    Neuropharmacology; 2019 Jun; 151():1-12. PubMed ID: 30940536
    [Abstract] [Full Text] [Related]

  • 2. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
    Dowie MJ, Bradshaw HB, Howard ML, Nicholson LF, Faull RL, Hannan AJ, Glass M.
    Neuroscience; 2009 Sep 29; 163(1):456-65. PubMed ID: 19524019
    [Abstract] [Full Text] [Related]

  • 3. Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.
    Laprairie RB, Kulkarni PM, Deschamps JR, Kelly MEM, Janero DR, Cascio MG, Stevenson LA, Pertwee RG, Kenakin TP, Denovan-Wright EM, Thakur GA.
    ACS Chem Neurosci; 2017 Jun 21; 8(6):1188-1203. PubMed ID: 28103441
    [Abstract] [Full Text] [Related]

  • 4. Enantiomer-specific positive allosteric modulation of CB1 signaling in autaptic hippocampal neurons.
    Mitjavila J, Yin D, Kulkarni PM, Zanato C, Thakur GA, Ross R, Greig I, Mackie K, Straiker A.
    Pharmacol Res; 2018 Mar 21; 129():475-481. PubMed ID: 29158048
    [Abstract] [Full Text] [Related]

  • 5. Methods to Quantify Cell Signaling and GPCR Receptor Ligand Bias: Characterization of Drugs that Target the Endocannabinoid Receptors in Huntington's Disease.
    Bagher AM, Laprairie RB, Kelly MEM, Denovan-Wright EM.
    Methods Mol Biol; 2018 Mar 21; 1780():549-571. PubMed ID: 29856035
    [Abstract] [Full Text] [Related]

  • 6. Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation.
    Thapa D, Cairns EA, Szczesniak AM, Kulkarni PM, Straiker AJ, Thakur GA, Kelly MEM.
    Molecules; 2020 Jan 20; 25(2):. PubMed ID: 31968549
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington's Disease Mouse Model.
    Sepers MD, Smith-Dijak A, LeDue J, Kolodziejczyk K, Mackie K, Raymond LA.
    J Neurosci; 2018 Jan 17; 38(3):544-554. PubMed ID: 29192125
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure.
    Garai S, Schaffer PC, Laprairie RB, Janero DR, Pertwee RG, Straiker A, Thakur GA.
    Bioorg Med Chem; 2021 Nov 15; 50():116421. PubMed ID: 34634617
    [Abstract] [Full Text] [Related]

  • 13. Positive allosteric modulation of the cannabinoid CB1 receptor potentiates endocannabinoid signalling and changes ERK1/2 phosphorylation kinetics.
    Green HM, Manning JJ, Greig IR, Ross RA, Finlay DB, Glass M.
    Br J Pharmacol; 2024 Oct 15; 181(19):3642-3662. PubMed ID: 38831545
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.
    Kedaigle AJ, Reidling JC, Lim RG, Adam M, Wu J, Wassie B, Stocksdale JT, Casale MS, Fraenkel E, Thompson LM.
    Hum Mol Genet; 2020 Jan 15; 29(2):202-215. PubMed ID: 31696228
    [Abstract] [Full Text] [Related]

  • 18. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice.
    Ooms M, Rietjens R, Rangarajan JR, Vunckx K, Valdeolivas S, Maes F, Himmelreich U, Fernandez-Ruiz J, Bormans G, Van Laere K, Casteels C.
    Neurobiol Aging; 2014 Dec 15; 35(12):2858-2869. PubMed ID: 25018107
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.